Trials / Unknown
UnknownNCT04631146
Efficacy and Safety of Camrelizumab in Real-World Study
Efficacy and Safety of Camrelizumab for Chinese NSCLC Patients: a Retrospective, Observational, Multicenter Real-World Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (estimated)
- Sponsor
- Guangdong Association of Clinical Trials · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Detailed description
Camrelizumab is a humanized antibody for cancer immunotherapy. The National Medical Products Administration (NMPA, China) approved camrelizumab as a first-line treatment of certain patients with NSCLC. This is a multicenter non-interventional study, NSCLC patients who have been treated with camrelizumab will be included. The main objective of this study is to evaluate the efficacy and safety of camrelizumab in the clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | PD-1 inhibitors |
Timeline
- Start date
- 2020-11-30
- Primary completion
- 2021-06-30
- Completion
- 2021-12-30
- First posted
- 2020-11-17
- Last updated
- 2020-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04631146. Inclusion in this directory is not an endorsement.